Own-developed non-urology products divested or out-licensed:
Photocure developed and commercialized a product for non-melanoma skin cancer and actinic keratosis, based on Photocure Technology®. Only affected tissue is removed, while leaving normal tissue unharmed. The product was divested to Galderma S.A. in 2009.
Photocure developed a breakthrough photodynamic cosmetic product specifically formulated to improve the overall appearance of skin, visibly reduce the outward signs of aging and minimize the appearance of pores. The product was sold to Bellus Medical in 2017.
Photocure developed Cevira®, a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. Cevira® is easily placed on the cervix by the gynecologist and removed by the patient, with no disruption of normal daily activities. The product was out-licensed to Asieris Meditech Co., Ltd for development and commercialization in 2019.